Anemia and erythrocytosis in patients after kidney transplantation.
Anemia is a highly prevalent disorder in recipients of renal allografts. Despite its frequent occurrence, there is still uncertainty with regard to treatment targets and treatment options. This includes questions on appropriate iron management, the choice and dosage of erythropoietin stimulating agents, criteria for the timing of treatment initiation and the targeted hemoglobin values. The review summarizes available data on recent therapeutic strategies for post transplant anemia, as well as for post transplant erythrocytosis, another hematological disorder, that has decreased in recent years.
Department of Nephrology and Transplantology, Medical University, Bialystok, Poland. jolmal@poczta.onet.pl
Jolanta
J
Malyszko
Rainer
R
Oberbauer
Bruno
B
Watschinger
D000368:Aged; D000740:Anemia / Q000209:etiology* / Q000628:therapy*; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006397:Hematinics / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000209:etiology* / Q000628:therapy*; D011183:Postoperative Complications / Q000209:etiology; D012307:Risk Factors; D014184:Transplantation, Homologous
D006397:Hematinics; D007166:Immunosuppressive Agents